Fluticasone Propionate: Discovery, Development, Safety and Pharmacovigilance
Fluticasone propionate is a synthetic, locally acting glucocorticoid whose development made it possible to treat inflammation in the airways, nasal passages and skin while limiting—but not abolishing—systemic corticosteroid exposure. Its story is unusual because the same drug substance reached patients through several delivery systems, each with a different anatomical target, dosing convention, clinical evidence base and safety profile. A case report that says only “fluticasone” can therefore be too imprecise for either medical assessment or regulatory listedness. [1–5]
Scope and nomenclature. This article is about fluticasone propionate (FP), including its single-ingredient inhaled, intranasal and topical uses and the attribution problems posed by combinations. It does not assign evidence for fluticasone furoate (FF) to FP. The two esters are pharmacologically active as intact, structurally distinct molecules; neither is simply an inactive prodrug releasing a common fluticasone base. A separate planned article will examine FF and its own products. This distinction matters when assessing inhaler switches, paediatric exposure, drug interactions and adverse reactions. [1]
- Fluticasone Propionate: Discovery, Development, Safety and Pharmacovigilance
- Discovery: designing a potent topical steroid
- The first clinical programmes: asthma and rhinitis
- Regulatory and commercial evolution
- Evidence beyond the original indications
- Pharmacokinetics: local efficacy, systemic exceptions
- Safety profile: local injury and systemic steroid effects
- Listedness: dated US and Irish public-label comparison
- Practical pharmacovigilance: building an interpretable case
- From individual reports to signal assessment
- Practical case-review checklist
- Key takeaways
- References
- Regulatory Note
Discovery: designing a potent topical steroid
The starting problem was familiar from earlier corticosteroid research: systemic glucocorticoids suppress inflammation but sustained systemic exposure can impair the hypothalamic–pituitary–adrenal (HPA) axis, growth, bone health and host defence. Researchers sought high anti-inflammatory potency at a local target, coupled with rapid inactivation of drug that escaped into the circulation. Glaxo's medicinal-chemistry programme selected fluticasone propionate from structure–activity studies of topically active steroids based on the androstane nucleus. G. H. Phillipps described the selection rationale in a 1990 account; S. M. Harding's contemporaneous human-pharmacology report examined the emerging clinical properties. [2,3]
The propionate ester contributes to receptor binding and tissue behaviour; it is not a disposable chemical label. High glucocorticoid-receptor affinity, lipophilicity, local tissue retention and extensive hepatic metabolism shaped the intended therapeutic window. Those features are not proof that every dose is free of systemic effects: the absorbed fraction, route, treatment duration, individual susceptibility and co-administered CYP3A inhibitors remain decisive. [1–4]
Mechanism and why the route matters
FP binds intracellular glucocorticoid receptors and changes transcriptional regulation of inflammatory pathways. The downstream effects include reduced inflammatory-cell recruitment, mediator production and mucosal swelling. In asthma, it is a controller that reduces airway inflammation over repeated use, not a fast bronchodilator for an acute attack. In allergic rhinitis, regular nasal administration reduces symptoms such as obstruction, rhinorrhoea, itching and sneezing. Topical dermatological preparations act at inflamed skin but may produce greater systemic exposure with occlusion, extensive treated area or damaged skin. [4–7]
After intranasal administration, much of a conventional spray is swallowed, but oral bioavailability of FP is extremely low because of poor absorption and extensive first-pass metabolism. For orally inhaled products, systemic absorption from the lung cannot be dismissed simply because swallowed drug is extensively metabolised. Device and particle deposition therefore matter. An HFA metered-dose aerosol, dry-powder device, conventional nasal pump and exhalation-delivery nasal system are not dose-for-dose substitutes. [4–7]
The first clinical programmes: asthma and rhinitis
Early asthma trials
By 1993, a double-blind paediatric asthma trial had randomised 258 children to fluticasone propionate dry powder 50 micrograms twice daily or placebo, alongside background care, for four weeks. This was early evidence that local anti-inflammatory treatment could improve control in children; it was not a lifelong safety study. A separate adult placebo-controlled trial tested inhaled FP 25, 100 and 500 micrograms twice daily for up to eight weeks. The proportion withdrawn for predefined worsening was 63% with placebo, compared with 23%, 13% and 4% in the respective active-dose groups. These results support anti-inflammatory efficacy within that study, not an assumption that the highest tested dose is optimal for every patient. [8,9]
Later comparative research evaluated FP against other inhaled corticosteroids, including beclometasone. In a 399-person persistent-asthma trial, fluticasone regimens improved several lung-function and symptom measures relative to the comparator regimens studied. However, nominal microgram strengths across inhalers cannot be treated as pharmacologically equivalent; delivery technology, formulation, dose range and endpoint selection must be considered before drawing conclusions. [10]
Rhinitis trials and the once-daily opportunity
A six-month randomised trial in 466 people with perennial allergic rhinitis compared FP nasal spray 200 micrograms once daily, 100 micrograms twice daily, beclometasone nasal spray and placebo. Active regimens improved nasal symptoms relative to placebo, and once-daily FP performed similarly to the twice-daily FP regimen in that trial. This evidence helped establish regular once-daily nasal therapy as a practical option. [11]
A smaller paediatric perennial-rhinitis trial recruited 127 children aged 5–11 years, with 106 evaluated. It reported symptom improvement with FP 100 micrograms once daily over four weeks. These studies establish efficacy in particular populations and formulations; they do not override the minimum ages or supply restrictions of any specific contemporary product label. [12]
The early evidence illustrates a recurring lesson in drug development: potency and low measured plasma concentrations can justify trials and support favourable average tolerability, but they cannot exclude uncommon local tissue injury, delayed endocrine effects or clinically important interactions that become visible with longer, broader use.
Regulatory and commercial evolution
The US prescribing information for FP nasal spray identifies 1994 as the initial US approval year for that nasal product. The broader development history includes topical skin preparations, conventional nasal sprays, inhaled dry powders and pressurised inhalers. Ireland's medicines register records an FP dry-powder Diskus authorisation in 1996 and a Flixotide Evohaler authorisation in 1999; these are product-specific national dates, not a claim about the first worldwide approval of the molecule. The US FP HFA inhaler label is tied to NDA 021433, and individual marketed or repackaged labels have their own revision histories. [4–7,13]
Glaxo and its successor businesses developed the original FP platform. Subsequent commercial evolution followed two partly independent paths: generic or authorised-generic presentations of established inhaled and nasal products, and delivery-system innovation. The 2014 US approval of Flonase Allergy Relief for over-the-counter use changed how consumers could obtain a 50-microgram nasal spray; it did not transform all FP products into non-prescription medicines. Different Irish FP products have distinct marketing-authorisation holders, legal supply categories and authorised ages. Product identification therefore remains essential even where the active ingredient is familiar. [4–7,13,14]
The US exhalation-delivery product XHANCE provided a second kind of innovation: rather than discovering another glucocorticoid, its developer OptiNose used a device intended to improve delivery to deeper nasal regions. The product received US authorisation for chronic rhinosinusitis with nasal polyps in 2017 and an additional indication for chronic rhinosinusitis without nasal polyps in 2024. Its evidence and instructions are specific to the exhalation system, not to every conventional nasal pump. [15–17]
| Milestone | What it demonstrates | What it does not establish |
|---|---|---|
| 1990 Glaxo selection and human pharmacology reports | Rational selection of a potent locally active steroid | An exact inventor or first-in-human date not verified in the cited records |
| 1993–94 asthma and rhinitis studies | Efficacy in selected trial populations | Lifelong endocrine safety or universal dose equivalence |
| 1994 US FP nasal initial approval | Regulatory availability of one nasal presentation | Approval of every other route |
| 1996 Irish Diskus authorisation | National inhaled dry-powder lifecycle | Global first launch date |
| 2014 US OTC nasal switch | New access model for a defined product | OTC status for inhalers or all countries |
| 2017/2024 US exhalation-delivery indications | Device-specific clinical and regulatory evolution | Interchangeability with conventional sprays |
A drug substance is not a device
For medication reconciliation, the minimum useful product description is FP + route + formulation + strength + device + dosing frequency + country. A nasal metered spray at 50 micrograms per actuation, a 44-microgram HFA inhaler and a 250-microgram dry-powder inhaler differ in delivered location and administration technique. Combination inhalers add another active ingredient and a different evidence base. A change from one inhaler to another can be clinically important even when the ingredient and stated micrograms appear similar. [4–7]
A practical error example is a patient instructed to use a nasal steroid who instead inhales an asthma controller through the mouth because both boxes say “fluticasone.” Another is an asthma patient treating acute wheeze with FP alone rather than the prescribed reliever. In neither case should the reviewer stop at the broad term “incorrect dose”; the route, device, training, timing and resulting exposure determine the safety narrative.
Evidence beyond the original indications
Chronic obstructive pulmonary disease and pneumonia
FP's anti-inflammatory action made it an ingredient in combination treatments studied in chronic obstructive pulmonary disease (COPD). The large TORCH trial compared salmeterol, FP, their combination and placebo in COPD over three years. Its primary mortality comparison for the combination versus placebo did not reach the conventional 0.05 significance threshold (reported P = 0.052), although other outcomes favoured active therapy. Pneumonia occurred more often in groups receiving inhaled FP. [18]
This is a clinically important negative or borderline finding: improvements in exacerbation-related measures do not justify rewriting an unsuccessful primary survival comparison as a proven mortality benefit. Nor can combination outcomes be credited entirely to FP. The UK Flixotide Accuhaler SmPC specifically lists pneumonia in COPD patients among adverse reactions and warns that pneumonia may resemble a COPD exacerbation. [6] This does not imply that an FP-only US asthma inhaler carries an identical COPD indication or frequency table.
In case assessment, a patient with COPD, advanced age, frequent exacerbations, smoking exposure and an FP-containing inhaler may develop pneumonia for several reasons. Dose, inhaled corticosteroid exposure, pathogen testing, imaging, severity, comorbidities and alternative causes should be evaluated. The product's indication and whether the patient was using a combination are part of the exposure definition.
Nasal polyposis and chronic rhinosinusitis
The NAVIGATE I and NAVIGATE II randomised trials evaluated exhalation-delivered FP in adults with chronic rhinosinusitis with nasal polyps. NAVIGATE I enrolled 323 participants and found improvements in both nasal congestion and polyp-grade endpoints with studied doses compared with the device placebo. NAVIGATE II also enrolled 323 participants and reported improvement in the coprimary endpoints. Local nasal events, particularly epistaxis, remained relevant. [15,16]
An open-label 12-month study involving 223 patients explored longer use of the exhalation system, but its single-arm design does not establish superiority over other treatments. The later US indication for chronic rhinosinusitis without nasal polyps should be traced to its own regulatory review and supporting evidence rather than inferred solely from the nasal-polyp trials. [17]
Skin disease and other formulations
FP is also used in topical dermatological preparations. A topical corticosteroid's safety depends on potency, treated area, skin barrier, duration, age and whether dressings increase absorption. The original medicinal-chemistry aim of topical activity applies, but an inhaled-asthma label is not a substitute for the particular cream or ointment's contraindications, age limits or application instructions. Cutaneous adverse events such as atrophy or steroid-associated dermatitis require their own exposure assessment. This article concentrates its dated public-label comparison on the nasal product for which both US and Irish primary texts were verified; it does not pretend to provide a universal listedness verdict for every FP skin product.
Pharmacokinetics: local efficacy, systemic exceptions
FP undergoes extensive CYP3A4-mediated metabolism, and swallowed FP generally contributes little systemic exposure. This does not mean that local delivery is equivalent to zero exposure. The nasal mucosa, lungs and damaged skin present different absorption conditions. Systemic glucocorticoid effects become more plausible with high or prolonged dosing, multiple corticosteroid products, susceptible patients and metabolic inhibition. [4–7]
The distinction between exposure and effect is central to pharmacovigilance. A low mean plasma concentration in a healthy-volunteer study does not exclude an individual developing Cushingoid features or adrenal suppression when a potent CYP3A inhibitor is added. Conversely, fatigue during steroid withdrawal is not automatically proof of FP toxicity; prior oral corticosteroid exposure and underlying disease must be reconstructed.
Safety profile: local injury and systemic steroid effects
The adverse-event profile of FP is best understood by first identifying the tissue exposed. Intranasal use primarily creates nasal and pharyngeal exposure; inhalation creates oropharyngeal and pulmonary exposure; dermatological use creates skin exposure. Systemic steroid effects remain possible across routes, but their likelihood and the evidence supporting each warning are not identical. [4–7]
Intranasal reactions: epistaxis, ulceration and healing
Epistaxis and nasal irritation are important nasal-spray reactions. The US prescription nasal label reports epistaxis in 6.9% of patients receiving 200 micrograms daily versus 5.4% on placebo in its specified clinical-trial table. Those percentages describe a particular trial pool, not a universal incidence for all FP sprays. The same label warns about nasal ulceration, local Candida infection, septal perforation and impaired wound healing; recent nasal surgery or trauma is relevant to risk. [4]
For a reported nosebleed, record which nostril was affected, duration, recurrence, trauma, spray direction toward the septum, concomitant anticoagulants or antiplatelets, other nasal medicines and examination findings. A patient who directs the nozzle at the nasal septum may experience focal irritation; this is a modifiable administration factor, not evidence that all epistaxis is solely technique-related. Persistent ulceration, septal perforation or severe bleeding needs appropriate clinical evaluation.
Inhaled reactions: candidiasis, dysphonia and bronchospasm
Inhaled FP may cause oral or pharyngeal candidiasis, hoarseness or throat irritation. The US HFA inhaler trial table includes candidiasis of the mouth/throat and dysphonia, with frequencies that vary across dose groups. Rinsing the mouth after inhalation, correct device technique and dose review can reduce local burden, although an established infection may require treatment. The inhaler is not a rescue medicine for acute bronchospasm. [5]
Paradoxical bronchospasm immediately after administration is a distinct potentially serious event and should not be confused with a gradually worsening asthma exacerbation. Assess onset in minutes, audible wheeze, peak-flow or spirometry where available, treatment response, formulation changes and alternative triggers. The US inhaler label also describes immediate hypersensitivity, including anaphylaxis. [5]
HPA-axis suppression and iatrogenic Cushing syndrome
HPA-axis suppression is the clinically consequential exception to the idea that a locally administered steroid is necessarily safe systemically. Patients may develop Cushingoid features during excess glucocorticoid exposure and adrenal insufficiency when exposure falls or during physiological stress. Abrupt cessation of high-dose corticosteroid therapy can be hazardous in selected patients; management requires individual clinical assessment. [4–7]
The most instructive interaction is with ritonavir and other potent CYP3A4 inhibitors, including cobicistat-containing regimens. A healthy-volunteer study described in the UK inhaled FP SmPC found that ritonavir substantially increased systemic FP exposure and reduced serum cortisol after intranasal administration. Postmarketing cases of Cushing syndrome and adrenal suppression have been reported. Both the US nasal and Irish nasal documents advise avoiding or carefully managing such combinations because of systemic corticosteroid risk. [4,6,7]
A useful report records all corticosteroid sources (nasal, inhaled, oral, injected, dermatological), the start and stop dates of interacting medicines, characteristic clinical findings, morning cortisol and ACTH stimulation testing if performed, and recovery after intervention. The direction of the interaction is crucial: inhibiting FP metabolism can make a previously tolerated local dose systemically consequential. A report of “Cushing syndrome on inhaled steroid” without the antiretroviral regimen is incomplete.
Children: growth and the interpretation of trials
The US inhaled FP label discusses growth-velocity reduction as a potential corticosteroid effect and recommends routine growth monitoring in children. Its cited 52-week paediatric inhalation-powder trial reported mean velocities of 6.32 cm/year with placebo, 6.07 cm/year with 50 micrograms twice daily and 5.66 cm/year with 100 micrograms twice daily; the label also notes potential confounding from puberty timing and dropout. These are product- and study-specific observations, not an exact predicted reduction for every child receiving any FP preparation. [5]
A longitudinal safety assessment should include growth charts, parental height context, pubertal stage, baseline asthma severity, cumulative corticosteroid burden and periods of uncontrolled disease. Growth changes are not equivalent to biochemical adrenal suppression, and neither can be ruled out solely by an absence of obvious Cushingoid appearance.
Other clinically relevant risks
The US nasal label warns about glaucoma and cataracts, hypersensitivity, immunosuppression and worsening infections. The inhaler label adds reduced bone mineral density and eosinophilic conditions that may emerge during oral-steroid reduction. Visual complaints warrant examination for ocular disease rather than automatic assignment to a specific corticosteroid. [4,5]
In patients with COPD, pneumonia risk requires special attention when FP is used in studied inhaled regimens. Underlying lung disease and infectious exposure complicate causality, but the UK inhaled SmPC explicitly includes pneumonia in COPD patients in its adverse-reaction table. [6,18] Local and systemic corticosteroid effects can coexist; for example, oral candidiasis and low cortisol may reflect both local deposition and increased systemic exposure.
Listedness: dated US and Irish public-label comparison
Assessed product pair, accessed 26 October 2026:
- United States: Apotex fluticasone propionate 50 micrograms per actuation nasal spray, prescription SPL set ID
3830675d-b45e-fc97-1f73-674b1fc38c80, DailyMed updated 11 September 2026, with prescribing-information text revised January 2021. Relevant sections: 4, 5, 6 and 7. [4] - Ireland (EU national authorisation): Haleon Ireland Flixonase Allergy Relief 50 micrograms per dose nasal spray, HPRA authorisation PA0678/095/001, SmPC revised July 2025 (PDF dated 24 July 2025). Relevant sections: 4.1–4.8. This is a pharmacy-supply, non-prescription product with defined restrictions, not an Irish inhaler or an EU-wide centrally authorised product. [7]
| Assessment | US prescription nasal spray [4] | Irish Flixonase Allergy Relief nasal spray [7] |
|---|---|---|
| Population and supply | Labelled for adults and children aged 4 years and older; prescription label | SmPC specifies adults 18 years and over and says not to use under 18; national non-prescription supply conditions |
| Maximum dosing in the assessed text | 200 micrograms/day (two sprays in each nostril once daily) | Standard two sprays per nostril daily; SmPC allows up to four sprays per nostril daily for short periods; seek local instructions |
| Epistaxis | Explicit adverse reaction in clinical trials; 6.9% at 200 micrograms vs 5.4% placebo in a specified table | Listed very common in SmPC section 4.8 |
| Nasal septal perforation/ulceration | Discussed in warnings and postmarketing adverse reactions | Septal perforation very rare; nasal ulcers included in section 4.8 without a clearly displayed frequency |
| Anaphylaxis/angioedema | Hypersensitivity including anaphylaxis appears in warnings and postmarketing information | Hypersensitivity/anaphylactic reactions and facial or tongue oedema very rare in section 4.8 |
| Eye effects | Glaucoma/cataracts in warnings and postmarketing information | Glaucoma, raised intraocular pressure and cataract very rare; blurred vision frequency unknown |
| HPA-axis effects and CYP3A inhibitors | Warnings/interaction precautions, not an assertion of a common trial-listed reaction | Warnings and interactions, including ritonavir/cobicistat; not equivalent to a section 4.8 frequency |
Interpretation. These are different regulatory presentations and different evidence summaries. “Very common” in the Irish SmPC must not be numerically equated to the US trial percentage, and the different labelled minimum ages are not evidence of a biological difference between the countries. In particular, an event appearing in a warning is not automatically a frequency-listed adverse reaction. Absence from a table does not establish that an event is absent from the whole product information. [4,7]
For inhaled FP, the US HFA label (DailyMed updated 20 January 2026; specific label text and revision history therein) and UK Flixotide Accuhaler SmPC (last updated 16 August 2023) provide route-specific context. The UK document is not an EU SmPC. An Irish Flixotide Diskus SmPC was indexed as updated 18 May 2026, but its full PDF was not reliably retrievable during this review; its exact adverse-reaction frequencies are therefore not asserted. A valid inhaler listedness decision must use the actual inhaler and local label, not transplant the nasal comparison. [5,6,19]
Finally, public-label listedness is not the same as expectedness under a company's applicable reference safety information, and neither is a determination of causality or seriousness. A valid case-level conclusion requires the identified product, event term, jurisdiction, relevant RSI and reporting context.
Practical pharmacovigilance: building an interpretable case
The first question in an FP case is not “is this a steroid reaction?” but which drug substance, product, route and exposure actually occurred? A patient may use FP nasal spray, an FP-containing asthma inhaler, a dermatological corticosteroid and an antiretroviral at the same time. A spontaneous report that collapses these into “fluticasone use” loses the information needed to assess biological plausibility, seriousness, listedness and preventability.
Case 1: iatrogenic Cushing syndrome after an interaction
Illustrative scenario, not an actual safety case. An adult using intranasal FP starts a ritonavir-boosted regimen and subsequently develops facial rounding, proximal weakness and easy bruising. A review should reconstruct the dose and start dates of both medicines, other steroid exposure, biochemical investigations, relevant diagnoses and the response to medically supervised changes. It should distinguish the FP reaction from the interaction mechanism and identify any suspected medication-error or prescribing-system contribution. The clinician's immediate treatment decisions are not determined by a pharmacovigilance algorithm; the safety team documents and evaluates the evidence. [4,6,7]
A useful follow-up request asks whether there were symptoms of adrenal insufficiency during withdrawal or acute illness, whether replacement corticosteroid was required, and whether an endocrinologist established the diagnosis. A change in cortisol concentration alone, without the clinical and exposure context, is not a complete account of iatrogenic Cushing syndrome.
Case 2: epistaxis after a nasal-device change
Illustrative scenario. A patient changes from a conventional nasal spray to an exhalation-delivery device, reports recurrent epistaxis and later has an examination showing mucosal ulceration. The two presentations differ in dose delivery and technique. The reporter should be asked about the actual device, priming and actuation, prior surgery, baseline rhinosinusitis, concurrent nasal medicines and whether the lesion preceded the switch. A formulation or device switch is a possible contributing factor, but the case cannot be assigned to a particular delivery mechanism without supporting facts. [4,15–17]
The medical assessment should preserve epistaxis and nasal ulceration as distinct events where both occurred. If the device did not deliver the intended dose, the associated product-quality or medication-error record may need parallel handling and reconciliation.
Case 3: pneumonia in a patient with COPD
Illustrative scenario. A patient with COPD receiving a salmeterol/FP inhaler is hospitalised for pneumonia. Record smoking, disease severity, prior exacerbations and pneumonia, inhaled-steroid dose and duration, recent systemic steroids, vaccination, microbiology, imaging and clinical outcome. The product contains two actives; an adverse-event assessment should not attribute a combination-product report entirely to the FP monotherapy evidence base. The TORCH signal context and relevant product labelling guide vigilance but do not prove causality in an individual patient. [6,18]
Case 4: apparent treatment failure or rescue-inhaler confusion
Illustrative scenario. A patient with asthma uses FP HFA only when suddenly breathless and reports “no effect.” The main issue may be incorrect use of a controller as a reliever, not intrinsic lack of pharmacological efficacy. Follow-up should capture prescription instructions, technique, rescue medication availability, exacerbation severity and whether the patient understood the difference. If a serious exacerbation occurred, the clinical event and any associated medication error need separate, accurate documentation. [5]
From individual reports to signal assessment
Spontaneous reporting is essential for unusual and delayed events, but its denominator is generally unknown. A cluster of Cushing syndrome reports among people receiving FP plus ritonavir is mechanistically plausible and warrants focused review, yet raw report counts cannot be converted into population incidence. Conversely, a controlled trial can estimate certain short-term reaction frequencies in its enrolled population but may be underpowered for rare endocrine or ocular outcomes. [4–7]
For an aggregate review, stratify cases at least by propionate versus furoate, nasal versus pulmonary versus cutaneous route, single ingredient versus combination, dose, paediatric/adult population, and presence of CYP3A inhibition. Use consistent medical case definitions: confirmed adrenal insufficiency should be distinguished from nonspecific fatigue; pneumonia from COPD exacerbation; local nasal ulceration from epistaxis; and device malfunction from intentional off-label use. Preserve the chronology of formulation changes and concomitant drugs. Such stratification is an analytical quality practice, not a claim that a particular regulator mandates this exact table.
When comparing regions, retain the label version and formulation used at the time of each assessment. National supply restrictions, different safety tables and formulation-specific warnings should not be erased in a pooled “fluticasone listedness” field. Signal-review documentation should explain data sources, selection rules, alternative explanations, medical adjudication, decision, implementation and subsequent effectiveness checks. In the EU, applicable pharmacovigilance legislation and current GVP govern relevant responsibilities; local procedures should translate those obligations into auditable actions without inventing a universal frequency for every workflow.
Practical case-review checklist
| Review domain | Minimum useful evidence |
|---|---|
| Substance identity | FP or FF; exact brand/generic, strength, batch if relevant |
| Exposure | Route, device, daily dose, start/stop, adherence, switching and technique |
| Indication | Asthma, rhinitis, chronic rhinosinusitis, dermatological disease or other use; product-specific authorisation |
| Co-medication | Ritonavir/cobicistat, other CYP3A inhibitors, other corticosteroids and relevant interacting treatments |
| Local events | Oral/nasal examination, candidiasis, ulceration, epistaxis, dysphonia, bronchospasm and onset |
| Systemic events | Cushingoid features, growth data, endocrine tests, bone/ocular findings, infection and competing causes |
| Seriousness and outcome | Hospitalisation, disability, medically important event, treatment, recovery and sequelae |
| Regulatory interpretation | Exact USPI or national SmPC, revision date, section, adverse-reaction listing versus warning, applicable RSI |
| Governance | Source traceability, follow-up, duplicate search, device/quality interfaces, medical review and documented decision |
For the underlying methods, see causality assessment in pharmacovigilance and listedness, expectedness and reference safety information. These general principles complement, but cannot replace, the dated product-specific comparison above.
Key takeaways
FP illustrates how the safety profile of one drug substance changes with where and how it is delivered. Glaxo's medicinal-chemistry strategy yielded a locally potent corticosteroid with extensive first-pass metabolism, but systemic effects remain possible, particularly with high exposure or CYP3A inhibition. Asthma and rhinitis trials supported its original uses; later delivery-system studies and the COPD experience added new evidence and distinct safety questions. The strongest practical safeguards are precise product identification, attention to interactions, proper technique and product-specific regional listedness. Fluticasone furoate is a different drug substance and must not be silently pooled with FP.
References
- Biggadike K. Fluticasone furoate/fluticasone propionate—different drugs with different properties. Clin Respir J. 2011;5:183–184. https://pmc.ncbi.nlm.nih.gov/articles/PMC3147057/
- Phillipps GH. Structure–activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990;84 Suppl A:19–23. https://pubmed.ncbi.nlm.nih.gov/2287791/
- Harding SM. The human pharmacology of fluticasone propionate. Respir Med. 1990;84 Suppl A:25–29. https://pubmed.ncbi.nlm.nih.gov/2287792/
- US National Library of Medicine. DailyMed, Apotex fluticasone propionate nasal spray, 50 micrograms/actuation, SPL set ID 3830675d-b45e-fc97-1f73-674b1fc38c80; SPL updated 11 September 2026; prescribing text revised January 2021. Accessed 26 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3830675d-b45e-fc97-1f73-674b1fc38c80
- US National Library of Medicine. DailyMed, Fluticasone Propionate HFA, prescription aerosol, SPL set ID ff1cf174-ae6f-45f0-a081-26a34e55f9ea; updated 20 January 2026. Accessed 26 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff1cf174-ae6f-45f0-a081-26a34e55f9ea
- UK electronic medicines compendium. Flixotide Accuhaler (fluticasone propionate), SmPC, last updated 16 August 2023. Accessed 26 October 2026. https://www.medicines.org.uk/emc/product/846/smpc
- Health Products Regulatory Authority (Ireland). Flixonase Allergy Relief 50 micrograms/dose nasal spray, SmPC, authorisation PA0678/095/001, text revised July 2025, PDF dated 24 July 2025. Accessed 26 October 2026. https://assets.hpra.ie/products/Human/19534/Licence_PA0678-095-001_24072025103621.pdf
- MacKenzie CA, et al. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr. 1993;152:856–860. https://pubmed.ncbi.nlm.nih.gov/8223792/
- Fluticasone Propionate Asthma Study Group. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994. https://pubmed.ncbi.nlm.nih.gov/7930300/
- A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol. 1999. https://pubmed.ncbi.nlm.nih.gov/10329812/
- Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone dipropionate. J Allergy Clin Immunol. 1993. https://pubmed.ncbi.nlm.nih.gov/8509578/
- Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children. Ann Allergy Asthma Immunol. 1997. https://pubmed.ncbi.nlm.nih.gov/9164361/
- Health Products Regulatory Authority (Ireland). Flixotide Diskus 100 micrograms inhalation powder, authorisation PA1077/044/010; register records 2 December 1996 authorisation. Accessed 26 October 2026. https://www.hpra.ie/find-a-medicine/for-human-use/authorised-medicines/details/24515
- GlaxoSmithKline. FDA approves Flonase Allergy Relief for over-the-counter sale in the United States. Sponsor announcement, 24 July 2014. https://www.gsk.com/en-gb/media/press-releases/fda-approves-flonase-allergy-relief-for-sale-over-the-counter-in-the-united-states/
- Sindwani R, et al. NAVIGATE I: randomised trial of exhalation delivery with fluticasone in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2019;33:69–82. https://pubmed.ncbi.nlm.nih.gov/30477309/
- Leopold DA, et al. NAVIGATE II: randomised trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143:126–134.e5. https://pubmed.ncbi.nlm.nih.gov/29928924/
- US Food and Drug Administration. XHANCE (fluticasone propionate) nasal spray, prescribing information for NDA 209022/S-019, 2024 indication expansion. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209022s019lbl.pdf
- Calverley PMA, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease (TORCH). N Engl J Med. 2007;356:775–789. https://pubmed.ncbi.nlm.nih.gov/17314337/
- Medicines.ie. Flixotide Diskus 250 micrograms, Irish SmPC listing updated 18 May 2026; full document not independently retrieved for this comparison. Accessed 26 October 2026. https://www.medicines.ie/medicines/flixotide-diskus-250mcg-32166/spc/1000
Regulatory Note
This is an educational review, not clinical advice or a substitute for the current locally authorised product information. US prescription nasal labelling, Irish non-prescription nasal SmPC, US inhaler labelling and UK inhaler SmPC refer to different presentations and must not be interchanged. Trial observations, adverse-reaction listings, label warnings, causal assessments, signal hypotheses and recommended operational practices have distinct evidentiary and regulatory meanings. Always consult the exact current product and jurisdiction before making clinical, listedness or regulatory reporting decisions.